For patients not currently taking pregabalin extended-release AND for patients currently taking pregabalin extended-release tablets, non-formulary pregabalin extended-release (Lyrica CR®) will be covered on the prescription drug benefit when the following criteria are met:

- Diagnosis of diabetic peripheral neuropathy (DPN) or postherpetic neuralgia (PHN) on the Problem List - AND -

- Prior adequate trial and failure of or contraindication or intolerance to formulary TCA\(^\dagger\), gabapentin, DULoxetine and 2 other agents (formulary TCA\(^\dagger\), traMADol, anticonvulsant, opioid, topical lidocaine, capsaicin, SNRI) [total 5 agents] - AND -

- Documented clinically significant intolerance to** pregabalin immediate-release (Lyrica), a non-formulary criteria-based medication.

** Documented failure or intolerance to the immediate-release formulation occurring after adjusting the dose and dosing interval and of a nature to be expected to improve with extended-release formulation.

-OR-

Dose change only: Patient previously met criteria and is already taking the drug.

\(^\dagger\) Formulary SSRIs = citalopram, fluoxetine, paroxetine, sertraline, escitalopram

\(^\dagger\) Formulary TCAs = nortriptyline, desipramine, amitriptyline.

Conversion Criteria for Neuropathy, Fibromyalgia and Musculoskeletal pain. (If using off-label for seizures, consult with Neurology):

Patient not currently taking an SSRI:
1. Adequate trial of gabapentin -AND-
2. Trial of SNRI -OR-
3. Trial of TCA
4. Trial of pregabalin immediate-release

Patient currently taking an SSRI:
1. Adequate trial of gabapentin
2. Adequate trial of pregabalin immediate-release